ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002

Avon Gives $3 Million To Expand CDC’s Screening Program

February 18, 1994

Two OAM Advisors Criticize Third over ACS Membership

July 23, 1993

Racial Differences In Survival Increase According To Stage

August 31, 2007

Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed

December 12, 1975

Collins, Lander, Botstein Win Albany Prize.

March 12, 2010